Loading...
XNAS
ALZN
Market cap2mUSD
Jul 16, Last price  
3.53USD
1D
11.36%
1Q
426.87%
IPO
-65.89%
Name

Alzamend Neuro Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
53.86%
Rev. gr., 5y
%
Revenues
0k
Net income
-10m
L-33.14%
-69,456-1,569,898-931,663-4,862,496-4,396,311-5,203,664-12,404,583-14,878,167-9,947,746
CFO
-8m
L-7.32%
-18,492-1,416,694-2,051,699-1,045,200-2,345,790-2,712,027-6,613,990-8,923,152-8,269,993

Profile

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
IPO date
Jun 15, 2021
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑04
Income
Revenues
Cost of revenue
9,988
14,894
Unusual Expense (Income)
NOPBT
(9,988)
(14,894)
NOPBT Margin
Operating Taxes
(145)
Tax Rate
NOPAT
(9,988)
(14,749)
Net income
(9,948)
-33.14%
(14,878)
19.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,252
989
BB yield
-52.07%
-278.05%
Debt
Debt current
301
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(75)
(5,141)
Cash flow
Cash from operating activities
(8,270)
(8,923)
CAPEX
(147)
Cash from investing activities
(147)
Cash from financing activities
3,652
200
FCF
(7,615)
(14,726)
Balance
Cash
376
5,141
Long term investments
Excess cash
376
5,141
Stockholders' equity
(54,020)
(44,063)
Invested Capital
51,727
47,108
ROIC
ROCE
435.51%
EV
Common stock shares outstanding
3,383
650
Price
0.71
29.91%
0.55
-46.34%
Market cap
2,405
575.97%
356
-41.27%
EV
2,330
10,098
EBITDA
(9,938)
(14,870)
EV/EBITDA
Interest
10
8
Interest/NOPBT